And I reiterate: Alfasigma already has a drug used
Post# of 72440
I checked -- Alfasigma's drug Xifaxan (Rifaxamin) is very, very expensive in the U.S. but within reason in Canada. It seems to be marketed by Salix in North America. Their first patent approval was May, 2004, and they have other patents as late at 2010.
This means they're planning for a future when generics for this drug will knock the price way down, and that future is not all that far away for them. They really NEED for Brilacidin to be developed.
https://www.drugpatentwatch.com/p/tradename/XIFAXAN